Conrad Chris Weihl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Conrad Chris Weihl has a total of 645 co-authors. Here are the top co-authors by number of shared publications:
Jil Daw
Department of Neurology, Washington University in St. Louis, St. Louis, MO, 63130, USA
9 shared publications- Andrew R. Findlay
Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
7 shared publications Sara Pittman
Department of Neurology, Washington University in St. Louis, St. Louis, MO, 63130, USA
7 shared publications- Chiseko Ikenaga
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
6 shared publications - Lindsay N. Alfano
Nationwide Children's Hospital, Columbus, OH
6 shared publications Sara K. Pittman
Department of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA
6 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6) , e200448
Natural History of Limb Girdle Muscular Dystrophy D1 (LGMDD1)
Background and ObjectivesLimb‐girdle muscular dystrophy type D1 (LGMDD1) is caused by dominantly inherited pathogenic variants in DNAJB6, a cochaperone of HSP70. Prior work has described the clinic...
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6) , e200448
Open AccessNatural History of Limb Girdle Muscular Dystrophy D1 (LGMDD1)
Background and ObjectivesLimb‐girdle muscular dystrophy type D1 (LGMDD1) is caused by dominantly inherited pathogenic variants in DNAJB6, a cochaperone of HSP70. Prior work has described the clinic...
- Open Access
VCP is a critical component for TDP-43 disaggregase activity in skeletal muscle
TDP-43 aggregates are a unifying pathological feature between several neurodegenerative diseases and myopathies. Mutations in the AAA ATPase protein VCP have been linked to TDP-43 proteinopathies in both brain and skeletal muscle including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and inclusion body myopathy (IBM). In the case of multisystem proteinopathy (MSP), patients with VCP mutations may present with combinations of these phenotypes. Of these MSP phenotypes IBM is the most common, affecting around 90% of patients. However, it is not well understood how mutations in VCP contribute to the accumulation of insoluble TDP-43 aggregates in the context of skeletal muscle. To study this further, we used in vitro and in vivo models of TDP-43 aggregation in skeletal muscle in the presence of VCP mutation or inhibition to study its effects on the ability to clear TDP-43 aggregates. Across multiple model systems we found that VCP disease mutations or inhibition causes a reduced capacity to clear insoluble TDP-43, suggesting a VCP loss of function in patients with VCP-related MSP.
Open AccessVCP is a critical component for TDP-43 disaggregase activity in skeletal muscle
TDP-43 aggregates are a unifying pathological feature between several neurodegenerative diseases and myopathies. Mutations in the AAA ATPase protein VCP have been linked to TDP-43 proteinopathies in both brain and skeletal muscle including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and inclusion body myopathy (IBM). In the case of multisystem proteinopathy (MSP), patients with VCP mutations may present with combinations of these phenotypes. Of these MSP phenotypes IBM is the most common, affecting around 90% of patients. However, it is not well understood how mutations in VCP contribute to the accumulation of insoluble TDP-43 aggregates in the context of skeletal muscle. To study this further, we used in vitro and in vivo models of TDP-43 aggregation in skeletal muscle in the presence of VCP mutation or inhibition to study its effects on the ability to clear TDP-43 aggregates. Across multiple model systems we found that VCP disease mutations or inhibition causes a reduced capacity to clear insoluble TDP-43, suggesting a VCP loss of function in patients with VCP-related MSP.
- Open Access
- 26 June 2026
- Published by Springer Nature in Acta Neuropathologica
- Vol. 151 (1)
VMA21 deficiency leads to autophagic dysregulation and altered vesicle trafficking in X-linked myopathy with excessive autophagy
X-Linked myopathy with excessive autophagy (XMEA) is a rare vacuolar myopathy caused by mutations in Vma21, an assembly chaperone required for vacuolar H⁺–ATPase (V-ATPase) function. However, the mechanisms linking Vma21 deficiency to progressive muscle pathology remain poorly understood, in part due to the lack of suitable animal models. To address this gap, we generated conditional Vma21 knockout mouse models to investigate the consequences of Vma21 loss in striated muscle. Combined deletion of Vma21 in skeletal and cardiac muscle resulted in early lethality driven by severe cardiomyopathy associated with autophagic dysregulation, preceding the development of skeletal muscle pathology. In contrast, inducible skeletal muscle-specific deletion of Vma21 produced progressive muscle weakness and myopathy characterized by centralized nuclei, fiber splitting, and increased fiber size variability. Affected skeletal muscle also recapitulated defining pathological hallmarks of XMEA, including basal lamina reduplication and autophagic vacuoles with sarcolemmal features (AVSFs). Ultrastructural analysis revealed membrane-bound vacuoles containing partially undegraded material that frequently accumulated at the subsarcolemmal region, together with clusters of vesicular structures. Notably, mutant muscle exhibited increased staining for the late endosomal/exosomal marker CD63, which strongly colocalized with the complement membrane attack complex C5b-9. A similar increase in CD63 staining and its colocalization with C5b-9 were observed in skeletal muscle biopsies from patients with XMEA. Together, these models faithfully recapitulate key pathological features of XMEA and identify the accumulation of CD63-positive structures and their colocalization with C5b-9 as previously unrecognized features of Vma21-deficient skeletal muscle, implicating altered vesicle trafficking in XMEA pathogenesis.
- 26 June 2026
- Published by Springer Nature in Acta Neuropathologica
- Vol. 151 (1)
Open AccessVMA21 deficiency leads to autophagic dysregulation and altered vesicle trafficking in X-linked myopathy with excessive autophagy
X-Linked myopathy with excessive autophagy (XMEA) is a rare vacuolar myopathy caused by mutations in Vma21, an assembly chaperone required for vacuolar H⁺–ATPase (V-ATPase) function. However, the mechanisms linking Vma21 deficiency to progressive muscle pathology remain poorly understood, in part due to the lack of suitable animal models. To address this gap, we generated conditional Vma21 knockout mouse models to investigate the consequences of Vma21 loss in striated muscle. Combined deletion of Vma21 in skeletal and cardiac muscle resulted in early lethality driven by severe cardiomyopathy associated with autophagic dysregulation, preceding the development of skeletal muscle pathology. In contrast, inducible skeletal muscle-specific deletion of Vma21 produced progressive muscle weakness and myopathy characterized by centralized nuclei, fiber splitting, and increased fiber size variability. Affected skeletal muscle also recapitulated defining pathological hallmarks of XMEA, including basal lamina reduplication and autophagic vacuoles with sarcolemmal features (AVSFs). Ultrastructural analysis revealed membrane-bound vacuoles containing partially undegraded material that frequently accumulated at the subsarcolemmal region, together with clusters of vesicular structures. Notably, mutant muscle exhibited increased staining for the late endosomal/exosomal marker CD63, which strongly colocalized with the complement membrane attack complex C5b-9. A similar increase in CD63 staining and its colocalization with C5b-9 were observed in skeletal muscle biopsies from patients with XMEA. Together, these models faithfully recapitulate key pathological features of XMEA and identify the accumulation of CD63-positive structures and their colocalization with C5b-9 as previously unrecognized features of Vma21-deficient skeletal muscle, implicating altered vesicle trafficking in XMEA pathogenesis.
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2)
Quantitative Measurement of Glycosylated ⍺-Dystroglycan as a Biomarker for Disease Severity in Limb-Girdle Muscular Dystrophy Type 2I/R9
Limb-girdle muscular dystrophy type 2I (LGMD2I/R9) is caused by biallelic variants in the gene for Fukutin-related protein (FKRP), an enzyme required for proper glycosylation of α-dystroglycan (⍺DG), a critical structural protein of the dystrophin glycoprotein complex. Hypoglycosylation of αDG results in impaired function of αDG, which in turn leads to chronic myocyte injury and muscular dystrophy. The “Biomarker Development in LGMD2I/R9” (MLB-01-001) natural history study explored glycosylated ⍺DG as a muscle biomarker for LGMD2I/R9 to support clinical trial design for the development of potential therapeutics. MLB-01-001 was a prospective, 12-month observational study of clinically affected participants 10–65 years of age with genetically confirmed LGMD2I/R9 at 11 academic centers in the United States and Denmark. Tibialis anterior (TA) muscle biopsies were obtained at baseline, month 6, month 9, and/or month 12 and measured for glycosylated ⍺DG levels relative to that of an unaffected human control using a validated, quantitative western blot assay. Of 96 participants enrolled, 71 participants underwent at least 1 TA biopsy (54 homozygous for the c.826C>A variant and 17 with other FKRP genotypes). Participants who were homozygous for the c.826C>A variant tended to be older, to be composed of a higher percentage of females, to have had less time since diagnosis, and to be composed of a greater percentage of ambulatory participants than those who had other FKRP genotypes. Glycosylated ⍺DG levels were consistently lower in LGMD2I/R9 participants than in the control at baseline (median 8.5% of control, interquartile range [IQR] 10.8%) and reflected disease severity by genotype, with c.826C>A homozygotes showing higher median glycosylated ⍺DG levels (10.5% of control, IQR 10.9%, n = 54) than participants with other FKRP genotypes (4.6% of control, IQR 4.3%, n = 17). Glycosylated αDG levels remained stable over 6–12 months. Glycosylated ⍺DG was consistently lower in participants with LGMD2I/R9 than in the unaffected control, reflected disease severity by genotype, and remained stable over 6–12 months, suggesting that it may be an appropriate biomarker for assessing the effect of potential therapies for LGMD2I/R9. ClinicalTrials.gov ID NCT04202627, first posted 17 Dec 2019.
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2)
Open AccessQuantitative Measurement of Glycosylated ⍺-Dystroglycan as a Biomarker for Disease Severity in Limb-Girdle Muscular Dystrophy Type 2I/R9
Limb-girdle muscular dystrophy type 2I (LGMD2I/R9) is caused by biallelic variants in the gene for Fukutin-related protein (FKRP), an enzyme required for proper glycosylation of α-dystroglycan (⍺DG), a critical structural protein of the dystrophin glycoprotein complex. Hypoglycosylation of αDG results in impaired function of αDG, which in turn leads to chronic myocyte injury and muscular dystrophy. The “Biomarker Development in LGMD2I/R9” (MLB-01-001) natural history study explored glycosylated ⍺DG as a muscle biomarker for LGMD2I/R9 to support clinical trial design for the development of potential therapeutics. MLB-01-001 was a prospective, 12-month observational study of clinically affected participants 10–65 years of age with genetically confirmed LGMD2I/R9 at 11 academic centers in the United States and Denmark. Tibialis anterior (TA) muscle biopsies were obtained at baseline, month 6, month 9, and/or month 12 and measured for glycosylated ⍺DG levels relative to that of an unaffected human control using a validated, quantitative western blot assay. Of 96 participants enrolled, 71 participants underwent at least 1 TA biopsy (54 homozygous for the c.826C>A variant and 17 with other FKRP genotypes). Participants who were homozygous for the c.826C>A variant tended to be older, to be composed of a higher percentage of females, to have had less time since diagnosis, and to be composed of a greater percentage of ambulatory participants than those who had other FKRP genotypes. Glycosylated ⍺DG levels were consistently lower in LGMD2I/R9 participants than in the control at baseline (median 8.5% of control, interquartile range [IQR] 10.8%) and reflected disease severity by genotype, with c.826C>A homozygotes showing higher median glycosylated ⍺DG levels (10.5% of control, IQR 10.9%, n = 54) than participants with other FKRP genotypes (4.6% of control, IQR 4.3%, n = 17). Glycosylated αDG levels remained stable over 6–12 months. Glycosylated ⍺DG was consistently lower in participants with LGMD2I/R9 than in the unaffected control, reflected disease severity by genotype, and remained stable over 6–12 months, suggesting that it may be an appropriate biomarker for assessing the effect of potential therapies for LGMD2I/R9. ClinicalTrials.gov ID NCT04202627, first posted 17 Dec 2019.
- Open Access
- 1 April 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 63, 106416
Natural history of limb girdle muscular dystrophy R1 (LGMDR1): a GRASP consortium study
- 1 April 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 63, 106416
Open AccessNatural history of limb girdle muscular dystrophy R1 (LGMDR1): a GRASP consortium study
- Open Access
- 6 March 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Translation of expanded CGG repeats in LRP12 associated oculopharyngodistal myopathy
Oculopharyngodistal myopathy (OPDM) is characterized by ptosis, ophthalmoparesis, dysphagia, and distal weakness. Myopathological features include rimmed v
- 6 March 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Open AccessTranslation of expanded CGG repeats in LRP12 associated oculopharyngodistal myopathy
Oculopharyngodistal myopathy (OPDM) is characterized by ptosis, ophthalmoparesis, dysphagia, and distal weakness. Myopathological features include rimmed v
- Open Access
- 7 January 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (4) , 283-292
Spectrum of dominant Charcot-Marie-Tooth disease due to SLC12A6 variants
Background: Heterozygous variants in SLC12A6 have recently been shown to cause dominant Charcot-Marie-Tooth disease (CMT). We aim to characterise the phenotype of patients with previously reported and novel heterozygous variants in the gene and understand any genotype-phenotype correlation. Methods: Patients were clinically and genetically assessed in sites from Europe, Australia, Brazil and the USA. All patients underwent whole exome or whole genome sequencing. Variants were classified using American College of Medical Genetics and Genomics criteria. Results: Twenty-three individuals from 13 families carried nine variants classified either as pathogenic/likely pathogenic or variants of uncertain significance segregating in multiple family members, including five novel variants. Forty-eight percent (11/23) were male with a mean age of disease onset of 15.7 years (range 1–45 years). Clinical phenotype varied dramatically with genotype; Arg207His and Ser647Pro caused a severe childhood-onset, sensory and motor, conduction-slowing neuropathy, whereas Gly552Asp caused a mild, adult-onset, sensory-predominant neuropathy, Thr991Ala an infantile-onset motor neuropathy, and the Met282Lys/Gly286Cys locus a complex, axonal neuropathy. Conclusions: Heterozygous variants in SLC12A6 can cause CMT of all clinical phenotypes, severity and age of onset, depending on the genotype. Such phenotypic diversity has not been described for any other CMT gene, and more work is needed to understand disease mechanisms to guide future therapeutic options.
- 7 January 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (4) , 283-292
Open AccessSpectrum of dominant Charcot-Marie-Tooth disease due to SLC12A6 variants
Background: Heterozygous variants in SLC12A6 have recently been shown to cause dominant Charcot-Marie-Tooth disease (CMT). We aim to characterise the phenotype of patients with previously reported and novel heterozygous variants in the gene and understand any genotype-phenotype correlation. Methods: Patients were clinically and genetically assessed in sites from Europe, Australia, Brazil and the USA. All patients underwent whole exome or whole genome sequencing. Variants were classified using American College of Medical Genetics and Genomics criteria. Results: Twenty-three individuals from 13 families carried nine variants classified either as pathogenic/likely pathogenic or variants of uncertain significance segregating in multiple family members, including five novel variants. Forty-eight percent (11/23) were male with a mean age of disease onset of 15.7 years (range 1–45 years). Clinical phenotype varied dramatically with genotype; Arg207His and Ser647Pro caused a severe childhood-onset, sensory and motor, conduction-slowing neuropathy, whereas Gly552Asp caused a mild, adult-onset, sensory-predominant neuropathy, Thr991Ala an infantile-onset motor neuropathy, and the Met282Lys/Gly286Cys locus a complex, axonal neuropathy. Conclusions: Heterozygous variants in SLC12A6 can cause CMT of all clinical phenotypes, severity and age of onset, depending on the genotype. Such phenotypic diversity has not been described for any other CMT gene, and more work is needed to understand disease mechanisms to guide future therapeutic options.
- 25 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (10) , e214291
Expert Consensus on Genetic Diagnostic Approaches for Patients With Limb-Girdle Muscular Dystrophy
Limb-girdle muscular dystrophy (LGMD) is the phenotypic description of a clinically and genetically diverse group of inherited neuromuscular disorders involving proximal muscles of the pelvic and shoulder girdles. There are currently over 30 different genetic forms of LGMD, and despite diagnostic advances, accurate diagnoses may be difficult to achieve. Although clinical diagnosis of a patient with a specific form of LGMD is possible in some cases, a precise and timely genetic diagnosis can be crucial to anticipate and prevent complications associated with particular genetic forms of LGMD (e.g., extramuscular manifestations such as cardiac, respiratory, or cognitive impairments). With the rapid pace of genetic testing advances, updates on training and education are imperative to support the correct use of these tests. We formed an expert consensus to provide an efficient diagnostic approach meant to empower clinicians in the use of genetic and other supportive tests. Informed selection and interpretation of a gene panel; use of genome or exome sequencing; and use of biochemical, imaging, pathology, and electromyography tests are discussed here. Ultimately, genetic testing should help to confirm a diagnosis and guide treatment decisions or counseling services.
- 25 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (10) , e214291
Expert Consensus on Genetic Diagnostic Approaches for Patients With Limb-Girdle Muscular Dystrophy
Limb-girdle muscular dystrophy (LGMD) is the phenotypic description of a clinically and genetically diverse group of inherited neuromuscular disorders involving proximal muscles of the pelvic and shoulder girdles. There are currently over 30 different genetic forms of LGMD, and despite diagnostic advances, accurate diagnoses may be difficult to achieve. Although clinical diagnosis of a patient with a specific form of LGMD is possible in some cases, a precise and timely genetic diagnosis can be crucial to anticipate and prevent complications associated with particular genetic forms of LGMD (e.g., extramuscular manifestations such as cardiac, respiratory, or cognitive impairments). With the rapid pace of genetic testing advances, updates on training and education are imperative to support the correct use of these tests. We formed an expert consensus to provide an efficient diagnostic approach meant to empower clinicians in the use of genetic and other supportive tests. Informed selection and interpretation of a gene panel; use of genome or exome sequencing; and use of biochemical, imaging, pathology, and electromyography tests are discussed here. Ultimately, genetic testing should help to confirm a diagnosis and guide treatment decisions or counseling services.
- 19 August 2025
- Published by Elsevier in Neuromuscular Disorders
- Vol. 54, 106207
In memoriam: Dr. Julaine Marie Florence (1953–2025)
- 19 August 2025
- Published by Elsevier in Neuromuscular Disorders
- Vol. 54, 106207
In memoriam: Dr. Julaine Marie Florence (1953–2025)
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (4) , e200265
Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy
Valosin Containing Protein-associated multisystem proteinopathy (VCP-MSP) is a progressive, autosomal dominant disorder caused by pathogenic variants in the VCP gene, resulting in a heterogeneous clinical presentation. Muscle biopsy findings are characteristic but not pathognomonic. This study aimed to comprehensively analyse VCP-related myopathology and explore correlations with clinical phenotypes, genetic variants, and disease progression. Muscle biopsy images and data were collected retrospectively from adults (≥18 years) with pathogenic or likely pathogenic VCP variants enrolled in the VCP Multicentre International Study. Biopsy data were standardized using the “Common Data Elements for Muscle Biopsy Reporting.” Variations in biopsy findings were analysed by biopsy site, time from disease onset, the four most common VCP variants, and clinical phenotypes. A total of 112 muscle biopsies were included. Most individuals were male (66.0%). The mean age at biopsy was 53.3 years (SD 10.0), with a mean disease duration of 6.5 years (SD 4.5). The most frequent VCP variant was c.464G>A (p.Arg155His) (18.8%). The top clinical phenotypes were isolated myopathy (37.5%), myopathy with Paget disease of bone (17.9%), and myopathy with motor neuron involvement (13.4%). The vastus lateralis was the most common biopsy site (34.8%), and 91% were open biopsies. Histopathologic findings included atrophic fibres (87.5%), rimmed vacuoles (72.3%), endomysial fibrosis (58.0%), and protein aggregates (51.8%), primarily p62 (60.3%) and VCP (36.2%). Degeneration niches with fibrofatty replacement and atrophic fibres were seen in 33.3% of biopsies without frequency differences by clinical phenotypes. There were no differences in biopsy findings among the 4 most common VCP gene variants, except for the absence of degeneration niches in muscle biopsies of 12 patients with c.277C>T (p.Arg93Cys). MRI data from 30 patients showed fat pockets corresponding to these niches and STIR hyperintensity correlated with inflammatory infiltrates in 42.9%. Concordance between clinical phenotype, biopsy, and neurophysiology was observed in only 49.4% of cases, indicating significant heterogeneity. VCP-MSP muscle biopsies consistently show myopathic or mixed patterns with rimmed vacuoles and p62/VCP-positive inclusions, regardless of clinical phenotype, age, or progression. Some lack vacuoles, challenging diagnosis. Discrepancies between clinical, neurophysiology, and biopsy findings should prompt consideration of VCP-MSP to improve detection and management.
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (4) , e200265
Open AccessMuscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy
Valosin Containing Protein-associated multisystem proteinopathy (VCP-MSP) is a progressive, autosomal dominant disorder caused by pathogenic variants in the VCP gene, resulting in a heterogeneous clinical presentation. Muscle biopsy findings are characteristic but not pathognomonic. This study aimed to comprehensively analyse VCP-related myopathology and explore correlations with clinical phenotypes, genetic variants, and disease progression. Muscle biopsy images and data were collected retrospectively from adults (≥18 years) with pathogenic or likely pathogenic VCP variants enrolled in the VCP Multicentre International Study. Biopsy data were standardized using the “Common Data Elements for Muscle Biopsy Reporting.” Variations in biopsy findings were analysed by biopsy site, time from disease onset, the four most common VCP variants, and clinical phenotypes. A total of 112 muscle biopsies were included. Most individuals were male (66.0%). The mean age at biopsy was 53.3 years (SD 10.0), with a mean disease duration of 6.5 years (SD 4.5). The most frequent VCP variant was c.464G>A (p.Arg155His) (18.8%). The top clinical phenotypes were isolated myopathy (37.5%), myopathy with Paget disease of bone (17.9%), and myopathy with motor neuron involvement (13.4%). The vastus lateralis was the most common biopsy site (34.8%), and 91% were open biopsies. Histopathologic findings included atrophic fibres (87.5%), rimmed vacuoles (72.3%), endomysial fibrosis (58.0%), and protein aggregates (51.8%), primarily p62 (60.3%) and VCP (36.2%). Degeneration niches with fibrofatty replacement and atrophic fibres were seen in 33.3% of biopsies without frequency differences by clinical phenotypes. There were no differences in biopsy findings among the 4 most common VCP gene variants, except for the absence of degeneration niches in muscle biopsies of 12 patients with c.277C>T (p.Arg93Cys). MRI data from 30 patients showed fat pockets corresponding to these niches and STIR hyperintensity correlated with inflammatory infiltrates in 42.9%. Concordance between clinical phenotype, biopsy, and neurophysiology was observed in only 49.4% of cases, indicating significant heterogeneity. VCP-MSP muscle biopsies consistently show myopathic or mixed patterns with rimmed vacuoles and p62/VCP-positive inclusions, regardless of clinical phenotype, age, or progression. Some lack vacuoles, challenging diagnosis. Discrepancies between clinical, neurophysiology, and biopsy findings should prompt consideration of VCP-MSP to improve detection and management.